Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: A European multicentre nested case-control study

Oriana Ciani, Erik Arendsen, Martin Romancik, Richard Lunik, Elisabetta Costantini, Manuel Di Biase, Giuseppe Morgia, Eugenia Fragalà, Tomaskin Roman, Marian Bernat, Giorgio Guazzoni, Rosanna Tarricone, Massimo Lazzeri

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objectives: To compare the clinical effectiveness of the intravesical administration of combined hyaluronic acid and chondroitin sulfate (HA+CS) versus current standard management in adult women with recurrent urinary tract infections (RUTIs). Setting: A European Union-based multicentre, retrospective nested case-control study. Participants: 276 adult women treated for RUTIs starting from 2009 to 2013. Interventions: Patients treated with either intravesical administration of HA+CS or standard of care (antimicrobial/immunoactive prophylaxis/probiotics/cranberry). Primary and secondary outcome measures: The primary outcome was occurrence of bacteriologically confirmed recurrence within 12 months. Secondary outcomes were time to recurrence, total number of recurrences, health-related quality of life and healthcare resource consumption. Crude and adjusted results for unbalanced characteristics are presented. Results: 181 patients treated with HA+CS and 95 patients treated with standard of care from 7 centres were included. The crude and adjusted ORs (95% CI) for the primary end point were 0.77 (0.46 to 1.28) and 0.51 (0.27 to 0.96), respectively. However, no evidence of improvement in terms of total number of recurrences (incidence rate ratio (95% CI), 0.99 (0.69 to 1.43)) or time to first recurrence was seen (HR (95% CI), 0.99 (0.61 to 1.61)). The benefit of intravesical HA+CS therapy improves when the number of instillations is ≥5. Conclusions: Our results show that bladder instillations of combined HA+CS reduce the risk of bacteriologically confirmed recurrences compared with the current standard management of RUTIs. Total incidence rates and hazard rates were instead nonsignificantly different between the 2 groups after adjusting for unbalanced factors. In contrast to what happens with antibiotic prophylaxis, the effectiveness of the HA+CS reinstatement therapy improves over time.

Original languageEnglish
Article numbere009669
JournalBMJ Open
Volume6
Issue number3
DOIs
Publication statusPublished - 2016

Fingerprint

Intravesical Administration
Chondroitin Sulfates
Hyaluronic Acid
Urinary Tract Infections
Case-Control Studies
Recurrence
Standard of Care
Therapeutics
Vaccinium macrocarpon
Antibiotic Prophylaxis
Quality of Health Care
Incidence
Probiotics
European Union
Quality of Life
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections : A European multicentre nested case-control study. / Ciani, Oriana; Arendsen, Erik; Romancik, Martin; Lunik, Richard; Costantini, Elisabetta; Di Biase, Manuel; Morgia, Giuseppe; Fragalà, Eugenia; Roman, Tomaskin; Bernat, Marian; Guazzoni, Giorgio; Tarricone, Rosanna; Lazzeri, Massimo.

In: BMJ Open, Vol. 6, No. 3, e009669, 2016.

Research output: Contribution to journalArticle

Ciani, O, Arendsen, E, Romancik, M, Lunik, R, Costantini, E, Di Biase, M, Morgia, G, Fragalà, E, Roman, T, Bernat, M, Guazzoni, G, Tarricone, R & Lazzeri, M 2016, 'Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: A European multicentre nested case-control study', BMJ Open, vol. 6, no. 3, e009669. https://doi.org/10.1136/bmjopen-2015-009669
Ciani, Oriana ; Arendsen, Erik ; Romancik, Martin ; Lunik, Richard ; Costantini, Elisabetta ; Di Biase, Manuel ; Morgia, Giuseppe ; Fragalà, Eugenia ; Roman, Tomaskin ; Bernat, Marian ; Guazzoni, Giorgio ; Tarricone, Rosanna ; Lazzeri, Massimo. / Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections : A European multicentre nested case-control study. In: BMJ Open. 2016 ; Vol. 6, No. 3.
@article{9bb65a7619e742b6862a12a855650df5,
title = "Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: A European multicentre nested case-control study",
abstract = "Objectives: To compare the clinical effectiveness of the intravesical administration of combined hyaluronic acid and chondroitin sulfate (HA+CS) versus current standard management in adult women with recurrent urinary tract infections (RUTIs). Setting: A European Union-based multicentre, retrospective nested case-control study. Participants: 276 adult women treated for RUTIs starting from 2009 to 2013. Interventions: Patients treated with either intravesical administration of HA+CS or standard of care (antimicrobial/immunoactive prophylaxis/probiotics/cranberry). Primary and secondary outcome measures: The primary outcome was occurrence of bacteriologically confirmed recurrence within 12 months. Secondary outcomes were time to recurrence, total number of recurrences, health-related quality of life and healthcare resource consumption. Crude and adjusted results for unbalanced characteristics are presented. Results: 181 patients treated with HA+CS and 95 patients treated with standard of care from 7 centres were included. The crude and adjusted ORs (95{\%} CI) for the primary end point were 0.77 (0.46 to 1.28) and 0.51 (0.27 to 0.96), respectively. However, no evidence of improvement in terms of total number of recurrences (incidence rate ratio (95{\%} CI), 0.99 (0.69 to 1.43)) or time to first recurrence was seen (HR (95{\%} CI), 0.99 (0.61 to 1.61)). The benefit of intravesical HA+CS therapy improves when the number of instillations is ≥5. Conclusions: Our results show that bladder instillations of combined HA+CS reduce the risk of bacteriologically confirmed recurrences compared with the current standard management of RUTIs. Total incidence rates and hazard rates were instead nonsignificantly different between the 2 groups after adjusting for unbalanced factors. In contrast to what happens with antibiotic prophylaxis, the effectiveness of the HA+CS reinstatement therapy improves over time.",
author = "Oriana Ciani and Erik Arendsen and Martin Romancik and Richard Lunik and Elisabetta Costantini and {Di Biase}, Manuel and Giuseppe Morgia and Eugenia Fragal{\`a} and Tomaskin Roman and Marian Bernat and Giorgio Guazzoni and Rosanna Tarricone and Massimo Lazzeri",
year = "2016",
doi = "10.1136/bmjopen-2015-009669",
language = "English",
volume = "6",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections

T2 - A European multicentre nested case-control study

AU - Ciani, Oriana

AU - Arendsen, Erik

AU - Romancik, Martin

AU - Lunik, Richard

AU - Costantini, Elisabetta

AU - Di Biase, Manuel

AU - Morgia, Giuseppe

AU - Fragalà, Eugenia

AU - Roman, Tomaskin

AU - Bernat, Marian

AU - Guazzoni, Giorgio

AU - Tarricone, Rosanna

AU - Lazzeri, Massimo

PY - 2016

Y1 - 2016

N2 - Objectives: To compare the clinical effectiveness of the intravesical administration of combined hyaluronic acid and chondroitin sulfate (HA+CS) versus current standard management in adult women with recurrent urinary tract infections (RUTIs). Setting: A European Union-based multicentre, retrospective nested case-control study. Participants: 276 adult women treated for RUTIs starting from 2009 to 2013. Interventions: Patients treated with either intravesical administration of HA+CS or standard of care (antimicrobial/immunoactive prophylaxis/probiotics/cranberry). Primary and secondary outcome measures: The primary outcome was occurrence of bacteriologically confirmed recurrence within 12 months. Secondary outcomes were time to recurrence, total number of recurrences, health-related quality of life and healthcare resource consumption. Crude and adjusted results for unbalanced characteristics are presented. Results: 181 patients treated with HA+CS and 95 patients treated with standard of care from 7 centres were included. The crude and adjusted ORs (95% CI) for the primary end point were 0.77 (0.46 to 1.28) and 0.51 (0.27 to 0.96), respectively. However, no evidence of improvement in terms of total number of recurrences (incidence rate ratio (95% CI), 0.99 (0.69 to 1.43)) or time to first recurrence was seen (HR (95% CI), 0.99 (0.61 to 1.61)). The benefit of intravesical HA+CS therapy improves when the number of instillations is ≥5. Conclusions: Our results show that bladder instillations of combined HA+CS reduce the risk of bacteriologically confirmed recurrences compared with the current standard management of RUTIs. Total incidence rates and hazard rates were instead nonsignificantly different between the 2 groups after adjusting for unbalanced factors. In contrast to what happens with antibiotic prophylaxis, the effectiveness of the HA+CS reinstatement therapy improves over time.

AB - Objectives: To compare the clinical effectiveness of the intravesical administration of combined hyaluronic acid and chondroitin sulfate (HA+CS) versus current standard management in adult women with recurrent urinary tract infections (RUTIs). Setting: A European Union-based multicentre, retrospective nested case-control study. Participants: 276 adult women treated for RUTIs starting from 2009 to 2013. Interventions: Patients treated with either intravesical administration of HA+CS or standard of care (antimicrobial/immunoactive prophylaxis/probiotics/cranberry). Primary and secondary outcome measures: The primary outcome was occurrence of bacteriologically confirmed recurrence within 12 months. Secondary outcomes were time to recurrence, total number of recurrences, health-related quality of life and healthcare resource consumption. Crude and adjusted results for unbalanced characteristics are presented. Results: 181 patients treated with HA+CS and 95 patients treated with standard of care from 7 centres were included. The crude and adjusted ORs (95% CI) for the primary end point were 0.77 (0.46 to 1.28) and 0.51 (0.27 to 0.96), respectively. However, no evidence of improvement in terms of total number of recurrences (incidence rate ratio (95% CI), 0.99 (0.69 to 1.43)) or time to first recurrence was seen (HR (95% CI), 0.99 (0.61 to 1.61)). The benefit of intravesical HA+CS therapy improves when the number of instillations is ≥5. Conclusions: Our results show that bladder instillations of combined HA+CS reduce the risk of bacteriologically confirmed recurrences compared with the current standard management of RUTIs. Total incidence rates and hazard rates were instead nonsignificantly different between the 2 groups after adjusting for unbalanced factors. In contrast to what happens with antibiotic prophylaxis, the effectiveness of the HA+CS reinstatement therapy improves over time.

UR - http://www.scopus.com/inward/record.url?scp=84962433758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962433758&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2015-009669

DO - 10.1136/bmjopen-2015-009669

M3 - Article

AN - SCOPUS:84962433758

VL - 6

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 3

M1 - e009669

ER -